• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

酪氨酸激酶抑制剂耐药增加非小细胞肺癌脑转移瘤立体定向放射治疗后脑放射性坏死的风险:一项多机构回顾性病例对照研究

Tyrosine Kinase Inhibitor Resistance Increased the Risk of Cerebral Radiation Necrosis After Stereotactic Radiosurgery in Brain Metastases of Non-small-Cell Lung Cancer: A Multi-Institutional Retrospective Case-Control Study.

作者信息

Zhuang Hongqing, Tao Liyuan, Wang Xin, Shi Siyu, Yuan Zhiyong, Wang Enmin, Chang Joe Y

机构信息

Department of Radiation Oncology, Peking University Third Hospital, Beijing, China.

Clinical Epidemiology Department, Peking University Third Hospital, Beijing, China.

出版信息

Front Oncol. 2020 Feb 11;10:12. doi: 10.3389/fonc.2020.00012. eCollection 2020.

DOI:10.3389/fonc.2020.00012
PMID:32117704
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7026471/
Abstract

This study aimed to investigate the relationship between the timing of stereotactic radiosurgery (SRS) intervention and the complications of cerebral radiation necrosis (CRN) in patients with brain metastases of lung adenocarcinoma who received tyrosine kinase inhibitor (TKI) treatment. A total of 361 targets from 257 patients with brain oligometastases of lung adenocarcinoma who received CyberKnife treatment between 2010 and 2017 were retrospectively collected from three CyberKnife centers. The difference in brain necrosis between patients with or without TKI application was statistically counted. Logistic regression analysis was used to analyze the effect of applying TKI on the occurrence of CRN in patients and the effect of SRS before and after TKI resistance on CRN. The rate of CRN in the TKI group was significantly higher than that in the non-TKI group. The incidence of brain necrosis in patients undergoing SRS after drug resistance was significantly higher than that in patients undergoing SRS before drug resistance. Regression analysis showed that combination of TKI with SRS, and SRS after TKI resistance were important influencing factors for CRN. Performing the SRS for brain metastases after TKI resistance worsened the occurrence of CRN of patients treated with TKI. Chinese clinical trial registry, http://www.chictr.org.cn/edit.aspx?pid=38395&htm=4, Registration number: ChiCTR1900022750.

摘要

本研究旨在探讨接受酪氨酸激酶抑制剂(TKI)治疗的肺腺癌脑转移患者中,立体定向放射外科(SRS)干预时机与脑放射性坏死(CRN)并发症之间的关系。回顾性收集了2010年至2017年间在三个射波刀中心接受射波刀治疗的257例肺腺癌脑寡转移患者的361个靶点。对应用或未应用TKI的患者之间的脑坏死差异进行了统计学计数。采用逻辑回归分析来分析应用TKI对患者CRN发生的影响以及TKI耐药前后SRS对CRN的影响。TKI组的CRN发生率显著高于非TKI组。耐药后接受SRS治疗的患者脑坏死发生率显著高于耐药前接受SRS治疗的患者。回归分析表明,TKI与SRS联合应用以及TKI耐药后进行SRS是CRN的重要影响因素。TKI耐药后对脑转移灶进行SRS会使接受TKI治疗的患者CRN的发生情况恶化。中国临床试验注册中心,http://www.chictr.org.cn/edit.aspx?pid=38395&htm=4,注册号:ChiCTR1900022750。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2bd3/7026471/51cf5b463042/fonc-10-00012-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2bd3/7026471/51cf5b463042/fonc-10-00012-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2bd3/7026471/51cf5b463042/fonc-10-00012-g0001.jpg

相似文献

1
Tyrosine Kinase Inhibitor Resistance Increased the Risk of Cerebral Radiation Necrosis After Stereotactic Radiosurgery in Brain Metastases of Non-small-Cell Lung Cancer: A Multi-Institutional Retrospective Case-Control Study.酪氨酸激酶抑制剂耐药增加非小细胞肺癌脑转移瘤立体定向放射治疗后脑放射性坏死的风险:一项多机构回顾性病例对照研究
Front Oncol. 2020 Feb 11;10:12. doi: 10.3389/fonc.2020.00012. eCollection 2020.
2
Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.酪氨酸激酶抑制剂初治表皮生长因子受体突变型非小细胞肺癌脑转移的管理:一项回顾性多机构分析。
J Clin Oncol. 2017 Apr 1;35(10):1070-1077. doi: 10.1200/JCO.2016.69.7144. Epub 2017 Jan 23.
3
Impacts of EGFR-mutation status and EGFR-TKI on the efficacy of stereotactic radiosurgery for brain metastases from non-small cell lung adenocarcinoma: A retrospective analysis of 133 consecutive patients.表皮生长因子受体突变状态和表皮生长因子受体酪氨酸激酶抑制剂对非小细胞肺腺癌脑转移立体定向放射外科疗效的影响:133 例连续患者的回顾性分析。
Lung Cancer. 2018 May;119:120-126. doi: 10.1016/j.lungcan.2018.03.013. Epub 2018 Mar 14.
4
Effects of an Epithelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Add-on in Stereotactic Radiosurgery for Brain Metastases Originating from Non-Small-Cell Lung Cancer.上皮生长因子受体-酪氨酸激酶抑制剂附加治疗在立体定向放射外科治疗非小细胞肺癌脑转移瘤中的作用
J Korean Neurosurg Soc. 2015 Sep;58(3):205-10. doi: 10.3340/jkns.2015.58.3.205. Epub 2015 Sep 30.
5
Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases.表皮生长因子受体突变的非小细胞肺癌发生脑转移患者延迟放疗的影响
Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):673-9. doi: 10.1016/j.ijrobp.2016.01.037. Epub 2016 Feb 2.
6
The impact of EGFR-TKI use on clinical outcomes of lung adenocarcinoma patients with brain metastases after Gamma Knife radiosurgery: a propensity score-matched analysis based on extended JLGK0901 dataset (JLGK0901-EGFR-TKI).EGFR-TKI 治疗对脑转移后行伽玛刀放射外科治疗的肺腺癌患者临床结局的影响:基于扩展的 JLGK0901 数据集(JLGK0901-EGFR-TKI)的倾向性评分匹配分析。
J Neurooncol. 2019 Oct;145(1):151-157. doi: 10.1007/s11060-019-03282-0. Epub 2019 Sep 5.
7
Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.脊柱立体定向放射外科联合酪氨酸激酶抑制剂治疗转移性肾细胞癌。
J Neurosurg Spine. 2016 Dec;25(6):766-774. doi: 10.3171/2016.4.SPINE16229. Epub 2016 Jul 8.
8
Multiinstitutional prospective observational study of stereotactic radiosurgery for patients with multiple brain metastases from non-small cell lung cancer (JLGK0901 study-NSCLC).多中心前瞻性观察研究立体定向放射外科治疗非小细胞肺癌多发脑转移患者(JLGK0901 研究-NSCLC)。
J Neurosurg. 2018 Dec 1;129(Suppl1):86-94. doi: 10.3171/2018.7.GKS181378.
9
Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects.寡复发预示着接受立体定向放射外科或立体定向放射治疗的非小细胞肺癌脑转移患者仅脑内寡转移灶的预后良好:一项对61例患者的多机构研究。
BMC Cancer. 2016 Aug 19;16(1):659. doi: 10.1186/s12885-016-2680-8.
10
Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery.表皮生长因子受体突变预测接受立体定向放射外科治疗的脑转移非小细胞肺癌患者的预后良好。
Radiother Oncol. 2018 Feb;126(2):368-374. doi: 10.1016/j.radonc.2017.10.010. Epub 2017 Oct 27.

引用本文的文献

1
Development of a recursive partitioning analysis for prediction of radiation necrosis following single-fraction stereotactic radiosurgery for intact brain metastases.用于预测完整脑转移瘤单次立体定向放射外科治疗后放射性坏死的递归划分分析的开发。
J Neurooncol. 2025 Sep;174(2):503-510. doi: 10.1007/s11060-025-05062-5. Epub 2025 May 13.
2
Concurrent afatinib and stereotactic body radiotherapy in patient with oligometastatic -mutated non-small cell lung cancer: a case report and literature review.阿法替尼与立体定向体部放疗同步治疗寡转移EGFR突变非小细胞肺癌:一例报告及文献综述
AME Case Rep. 2025 Apr 8;9:50. doi: 10.21037/acr-24-174. eCollection 2025.
3

本文引用的文献

1
Diagnosis and Management of Radiation Necrosis in Patients With Brain Metastases.脑转移瘤患者放射性坏死的诊断与管理
Front Oncol. 2018 Sep 28;8:395. doi: 10.3389/fonc.2018.00395. eCollection 2018.
2
Brain Radiation Necrosis: Current Management With a Focus on Non-small Cell Lung Cancer Patients.脑放射性坏死:以非小细胞肺癌患者为重点的当前管理方法
Front Oncol. 2018 Sep 5;8:336. doi: 10.3389/fonc.2018.00336. eCollection 2018.
3
Characteristics of Radiotherapy Trials Compared With Other Oncological Clinical Trials in the Past 10 Years.
A Case of Ramucirumab for Radiation Necrosis Following Stereotactic Radiotherapy for Brain Metastases From Lung Cancer.
雷莫西尤单抗治疗肺癌脑转移立体定向放射治疗后放射性坏死1例
Cureus. 2024 Sep 29;16(9):e70460. doi: 10.7759/cureus.70460. eCollection 2024 Sep.
4
Safety and efficacy of consolidative stereotactic radiotherapy for oligo-residual EGFR-mutant non-small cell lung cancer after first-line third-generation EGFR-tyrosine kinase inhibitors: a single-arm, phase 2 trial.一线使用第三代表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)治疗后,对寡残留EGFR突变型非小细胞肺癌进行巩固性立体定向放射治疗的安全性和有效性:一项单臂2期试验。
EClinicalMedicine. 2024 Sep 26;76:102853. doi: 10.1016/j.eclinm.2024.102853. eCollection 2024 Oct.
5
The dilemma of radiation necrosis from diagnosis to treatment in the management of brain metastases.脑转移瘤管理中从诊断到治疗的放射性坏死困境。
Neuro Oncol. 2024 Mar 4;26(12 Suppl 2):S56-S65. doi: 10.1093/neuonc/noad188.
6
Intracranial Outcomes of De Novo Brain Metastases Treated With Osimertinib Alone in Patients With Newly Diagnosed EGFR-Mutant NSCLC.在新诊断的表皮生长因子受体(EGFR)突变的非小细胞肺癌(NSCLC)患者中,单独使用奥希替尼治疗初发性脑转移的颅内结局
JTO Clin Res Rep. 2023 Nov 19;4(12):100607. doi: 10.1016/j.jtocrr.2023.100607. eCollection 2023 Dec.
7
New prognostic system specific for epidermal growth factor receptor-mutated lung cancer brain metastasis.针对表皮生长因子受体突变型肺癌脑转移的新型预后系统
Front Oncol. 2023 Mar 20;13:1093084. doi: 10.3389/fonc.2023.1093084. eCollection 2023.
8
International consensus on radiotherapy in metastatic non-small cell lung cancer.转移性非小细胞肺癌放射治疗的国际共识
Transl Lung Cancer Res. 2022 Sep;11(9):1763-1795. doi: 10.21037/tlcr-22-644.
9
[Expert Consensus on the Treatment of Antiangiogenic Agents for Radiation Brain Necrosis].《放射性脑坏死抗血管生成药物治疗专家共识》
Zhongguo Fei Ai Za Zhi. 2022 May 20;25(5):291-294. doi: 10.3779/j.issn.1009-3419.2022.101.18. Epub 2022 May 16.
10
Role of shear wave elastography as an adjunct to axillary ultrasonography in predicting nodal metastasis in breast cancer patients with suspicious nodes.剪切波弹性成像在腋窝超声检查可疑淋巴结的乳腺癌患者中预测淋巴结转移的作用。
Br J Radiol. 2022 Jun 1;95(1134):20220055. doi: 10.1259/bjr.20220055. Epub 2022 Mar 28.
过去 10 年放疗试验与其他肿瘤临床试验的特点比较。
JAMA Oncol. 2018 Aug 1;4(8):1073-1079. doi: 10.1001/jamaoncol.2018.0887.
4
Combined irradiation and targeted therapy or immune checkpoint blockade in brain metastases: toxicities and efficacy.脑转移瘤的联合放疗和靶向治疗或免疫检查点阻断:毒性和疗效。
Ann Oncol. 2017 Dec 1;28(12):2962-2976. doi: 10.1093/annonc/mdx408.
5
Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model.贝伐珠单抗在 EGFR 突变型 NSCLC 异种移植模型中对抗 VEGF 依赖性耐药。
Int J Oncol. 2017 Aug;51(2):425-434. doi: 10.3892/ijo.2017.4036. Epub 2017 Jun 8.
6
Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.酪氨酸激酶抑制剂初治表皮生长因子受体突变型非小细胞肺癌脑转移的管理:一项回顾性多机构分析。
J Clin Oncol. 2017 Apr 1;35(10):1070-1077. doi: 10.1200/JCO.2016.69.7144. Epub 2017 Jan 23.
7
EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases.表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)联合全脑放疗(WBRT)并未为非小细胞肺癌(NSCLC)伴表皮生长因子受体(EGFR)突变和脑转移患者带来生存获益,除 TKIs 单药治疗外。
J Thorac Oncol. 2016 Oct;11(10):1718-28. doi: 10.1016/j.jtho.2016.05.013. Epub 2016 May 26.
8
A study on the evaluation method and recent clinical efficacy of bevacizumab on the treatment of radiation cerebral necrosis.贝伐单抗治疗放射性脑坏死的评估方法及近期临床疗效研究
Sci Rep. 2016 Apr 12;6:24364. doi: 10.1038/srep24364.
9
Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases.表皮生长因子受体突变的非小细胞肺癌发生脑转移患者延迟放疗的影响
Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):673-9. doi: 10.1016/j.ijrobp.2016.01.037. Epub 2016 Feb 2.
10
Association between EGFR-TKI resistance and efficacy of radiotherapy for brain metastases from EGFR-mutant lung adenocarcinoma.表皮生长因子受体酪氨酸激酶抑制剂耐药与表皮生长因子受体突变型肺腺癌脑转移放疗疗效的关系。
Anticancer Res. 2013 Apr;33(4):1649-55.